Skip to main content

Rybelsus® vs. Sitagliptin 100 mg (PIONEER 3 Study)

This video discusses the trial-design and outcomes of the PIONEER 3 study. PIONEER 3 was a 78-week, phase 3a, randomized, double-blind, double-dummy, multinational trial enrolling 1864 adults with type 2 diabetes.

Play
Pause
Skip
Volume
Chapters
Transcript
References
video_su
Fullscreen

Rybelsus® vs. Sitagliptin 100 mg (PIONEER 3 Study)

Chapters
Transcript
References

Return to overview

Transcripts

Return to overview

References